SCHEMBL5600244

SCHEMBL5600244

Cc1cccc(C)c1-c1ccc(C)c(N2[C]N(c3c(C)ccc(-c4c(C)cccc4C)c3C)C(=Cc3ccccc3)C2)c1C

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.33
AKT2 P31751 2/20 0.33
AKT3 Q9Y243 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317911 0.73 DPP4 (0.34)
SCHEMBL5616226 0.64
SCHEMBL13064167 0.55 ALDH1A1 (0.54)
SCHEMBL11741027 0.55 MYC (0.48)
SCHEMBL28899579 0.54 MYC (0.58)
SCHEMBL623217 0.54 ALDH1A1 (0.38)
SCHEMBL13019332 0.53 SCN4A (0.36)
SCHEMBL1133067 0.52 MYC (0.56)
SCHEMBL23003867 0.51 POLB (0.46) AKT2
SCHEMBL31264394 0.51 ALDH1A1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403854-B2 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2016-08-02 US disclosed
US-20140288319-A1 CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-09-25 US disclosed
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-07-05 US disclosed
US-20040097745-A9 Stereospecific disproportionation of 1,2-disubstituted hydrocarbons in the cis configuration, using metal compounds as catalysts; catalysis GRUBBS ROBERT H (US) 2004-05-20 US disclosed
US-20030100776-A1 Allows for substitution of functional groups within the olefin without comprising efficiency of metathesis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288319-A1 CROSS-METATHESIS REACTION OF FUNCTIONALIZED AND SUBSTITUTED OLEFINS USING GROUP 8 TRANSITION METAL CARBENE COMPLEXES AS METATHESIS CATALYSTS OXER1, OSTC, OXSR1 AKT1 1066/4885AKT2 934/4885AKT3 2141/4885
US-20070155975-A1 Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts OXER1, OSTC, OXSR1 AKT1 1066/4885AKT2 934/4885AKT3 2141/4885
US-20030100776-A1 Allows for substitution of functional groups within the olefin without comprising efficiency of metathesis OXER1, OSTC, SQLE AKT1 2105/4885AKT2 1879/4885AKT3 2990/4885
US-20040097745-A9 Stereospecific disproportionation of 1,2-disubstituted hydrocarbons in the cis configuration, using metal compounds as catalysts; catalysis OXER1, OSTC, DUOX1 AKT1 2316/4885AKT2 1863/4885AKT3 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.